NCT05284331

Brief Summary

Articular Implant Infection (AII) is itself a complicated diagnosis and a challenging condition to treat. In elderly patients, the application of existing recommendations is impeded by multiple frailties For a better knowledge of the long-term consequences of AII in elderly patient, the investigators conduct a prospective, multicentric study, whitch aim this is to better evaluate the burden of AII on elderly patients, in terms of quality of life. Secondly, the investigators would like to identify the factors that influence the prognosis, in order to guide further prospective research.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 3, 2021

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

September 24, 2021

Completed
6 months until next milestone

First Posted

Study publicly available on registry

March 17, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 28, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 28, 2023

Completed
Last Updated

March 30, 2023

Status Verified

March 1, 2023

Enrollment Period

2.1 years

First QC Date

September 24, 2021

Last Update Submit

March 28, 2023

Conditions

Keywords

Articular Implant Infection

Outcome Measures

Primary Outcomes (2)

  • Changes in the EQ-5D-5L quality of life score

    the EQ-5D-5L questionnaire is a European quality of life scale: a first part with questions called "EQ-5D descriptive system" comprising 5 items: mobility, self-care, usual activities, pain and discomfort, anxiety and depression; each item is rated from 1 to 5; 1 corresponding to "no problem", "5" representing "extreme problems or total disability Changes in the EQ-5D-5L quality of life score, 1 year after the onset of symptoms will be evaluated

    1 year

  • Changes in the EQ-5D-VAS assessing the patient's general condition, completed by the patient

    the EQ-5D-5L questionnaire is completed by a visual analogue scale, called "EQ-5D VAS"; it consists of a 20 cm line, graduated from 0 to 100, where the patient has to indicate how he/she evaluates his/her current state of health, 0 being the worst possible state and 100 the best; Changes in the "EQ-5D VAS" wil be evaluated 1 year after the onset of symptoms.

    1 year

Study Arms (1)

follow-up visit at 6 months and 1 year after inclusion.

OTHER

addition of a follow-up visit at 6 months and 1 year after inclusion. No treatment will be given specifically for this study. Other visits are part of the normal and usual rhythm of follow-up and evaluation of treatment in these patients

Other: addition of two follow-up visits post infection

Interventions

Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection. No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection

follow-up visit at 6 months and 1 year after inclusion.

Eligibility Criteria

Age75 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • hospitalized in infectious diseases, surgery, post-emergency unit, or geriatrics,
  • diagnosed with a hip or knee prosthesis infection in the previous month according to the SPILF criteria (2009)(1).

You may not qualify if:

  • Above criteria not met,
  • Patient refusal,
  • Mild cognitive impairment or more significant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Métropole Savoie

Chambéry, 73000, France

Location

MeSH Terms

Conditions

InfectionsInflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • PEJU Martin, Physician

    Centre Hospitalier Metropole Savoie

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2021

First Posted

March 17, 2022

Study Start

March 3, 2021

Primary Completion

March 28, 2023

Study Completion

March 28, 2023

Last Updated

March 30, 2023

Record last verified: 2023-03

Locations